Characterization of alpha-1-acid glycoprotein as a potential biomarker for breast cancer

Bioengineered. 2022 Mar;13(3):5818-5826. doi: 10.1080/21655979.2022.2036303.

Abstract

Breast cancer is a malignant tumor that poses a serious threat to the health of women worldwide. The early diagnosis of patients with cancer or those at high risk remains difficult, which makes treatment challenging. Therefore, the study of diagnostic biomarkers for early detection of cancer is very important. AGP biomarkers are expected to be potential biomarkers for early detection of breast cancer. This study aimed to explore the potential of alpha-1-acid glycoprotein (AGP) as a biomarker for the diagnosis of breast cancer. The results revealed that the expression of AGP was high in breast cancer cells and tissues and was higher at stage IV than at stages III and II. Knockdown of ORM1, which encodes AGP, in MCF-7 cells suppressed the production of the inflammatory factors interleukin (IL)-1β, IL-8, and tumor necrosis factor-α. These results suggest that AGP can serve as a therapeutic target and/or diagnostic marker for breast cancer. Overall, we found that AGP can serve as a biomarker for breast cancer and inhibit secretion of related pro-inflammatory facto by blocking ORM1 expression.

Keywords: Breast cancer; alpha-1-acid glycoprotein; biomarker; immunohistochemistry.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Breast Neoplasms* / diagnosis
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / metabolism
  • Female
  • Humans
  • MCF-7 Cells
  • Orosomucoid* / metabolism
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Biomarkers
  • Orosomucoid
  • Tumor Necrosis Factor-alpha

Grants and funding

The present study was financially supported by the Hunan Provincial Technology Innovation Guidance Program—Clinical Medical Technology Innovation Guide Project (No. 2020SK50402).